0 CHECKOUT

Mesenchymal Stem Cells - Advances & Applications

  • ID: 3498983
  • November 2015
  • Region: Global
  • 250 Pages
  • BioInformant
1 of 4
Opportunities for Commercializing Mesenchymal Stem Cells

FEATURED COMPANIES

  • Anterogen Co., Ltd.
  • CellTherapies P/L
  • Cynata Therapeutics Ltd.
  • Kite Pharma Inc.
  • NuVasive Inc.
  • PromoCell
  • MORE

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. Because of their unique capacity to form structural tissues, MSCs also being explored for use in 3D printing applications.

The report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine (RM) and cell therapy (CT) industries.

It also explores recent advances in MSC products and technologies, identifies research priorities by market segment, READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Anterogen Co., Ltd.
  • CellTherapies P/L
  • Cynata Therapeutics Ltd.
  • Kite Pharma Inc.
  • NuVasive Inc.
  • PromoCell
  • MORE

1. Executive Summary

2. Report Overview
2.1 Target Demographic
2.2 Key Findings
2.3 Statement of the Report
2.4 Purpose
2.4.1 To Survey Recent MSC Advancements
2.4.2 To Provide a Snapshot of the Global MSC Market
2.4.3 To Assess Opportunities for Commercialization
2.4.4 To Identify Major Market Players and Assess the Competitive Environment
2.4.5 To Identify Existing and Emerging Trends
2.4.6 To Identify Critical Opportunities and Threats within the MSC Market

3. Research Methodology
3.1 Input Sources
3.2 Research & Analysis Methodologies
3.3 Criteria for Identiyfing MSC Market Leaders
3.3.1 Size of Company
3.3.2 Type of Product/Services
3.3.2 Degree of Specialization
3.3.4 Patent Positions
3.3.5 Business Reputation
3.3.6 Financial Strength
3.3.7 Partnerships
3.3.8 Certifications

4. Mesenchymal Stem Cell (MSC Definitions & Nomenclature)
4.1. Definition
4.2. Alternative Nomenclature
4.2.1 Mesenchymal Stem Cell
4.2.2 Marrow Stromal Cell (or Mesenchymal Stromal Cell)
4.2.3 Multipotent Stromal Cell
4.2.4 Colony-Forming Unit-fibroblasts

5. MSC Criteria & Characteristics
5.1 Discovery - Key Dates in the Discovery of Mesenchymal Stem Cells
5.2 Physical Assessment
5.3 Functional Attributes
5.4. Benefits of MSCs Relative to Other Stem Cells
5.4.1 Well-Characterized
5.4.2 Non-Controversial
5.4.3 Diverse Differentiation Potential
5.4.4 Ease of Growth in Culture
5.4.5 Flexible Propagation
5.4.6 Clinically Relevant Volumes
5.4.7 Role as Regulatory Cells
5.4.8 Delivery of Gene Products
5.4.9 Favorable Immune Status
5.4.10 Commercially Available Research Tools

6. MSC Isolation Sources
6.1 Adult Sources
6.2 Fetal Sources

7. Commercial Interest In MSC
7.1 Cell Types Derived from MSCs
7.2 Therapeutic Potential of MSCs

8. Introduction To Regenerative Medicine (RM Industry)
8.1 Regenerative Medicine (RM and Advanced Therapies Industry: A Brief Overview)
8.2 Global Breakdown of Regenerative Medicine (RM Industry by Region)
8.3 Breakdown of Global RM Companies by Type
8.4 Number of RM Clinical Trials by Phase of Development
8.5 Major Financial Events in the RM Industry
8.6 Major Partnerships and Acquisitions in RM Industry
8.7 Major Regulatory Milestones in RM Industry
8.8 Major Pharma and Biotech Companies Active in Advanced Therapies
8.9 Major Corporate Partnerships in RM Industry
8.10 Anticipated Major RM Clinical Events

9. Introduction To The Stem Cell Therapy Industry
9.1 Types of Stem Cells Used in Cell Therapy
9.1.1 Human Embryonic Stem Cells
9.1.2 Induced Pluripotent Stem Cells
9.1.3 Mesenchymal Stem Cells (MSCs)
9.1.4 Hematopoietic Stem Cells
9.1.5 Adipose Stem Cells (ASCs)
9.1.6 Neural Stem Cells (NSCs)
9.2 Types of Stem Cells Used in Cell Therapy, by Differentiation Potential
9.2.1 Totipotent (or Omnipotent Stem Cells)
9.2.2 Pluripotent Stem Cells
9.2.3 Multipotent Stem Cells
9.2.4 Oligopotent stem cells
9.2.5 Unipotent Stem Cells

10. Cell Therapy (CT Products: Successes And Failures)
10.1 Cell Therapy Product Candidates in Late-Stage Clinical Development
10.2 Cell Therapy Products Being Developed for Cardiovascular Indication
10.3 Cell Therapy Products Being Developed for Other Indications
10.4 Major Commercially Available Cell Therapy Products
10.5 Cell Therapy Products Approved in South Korea
10.6 Major Cell Therapies in Phase III
10.6.1 Prochymal
10.6.2 Mesenchymal Precursor Cell (MPC)
10.6.3 MyoCell
10.6.4 Ixmyelocel-T
10.6.5 ELAD
10.6.6 HP802
10.6.7 StemEx (Carlecortemcel-L)
10.6.8 LaViv
10.6.9 GSK 2696273
10.6.10 Renew
10.6.11 NT-501 (Renexus)
10.6.12 Neocart
10.6.13 DeNovo ET
10.6.14 MACI
10.7 Clinical Trial Failures in Cell Therapy
10.7.1 Failure of Phase II for MultiStem
10.7.2 Failure of Cardio 133 Trial
10.7.3 Termination of AlloCure’s ACT-AKI Trial
10.7.4 Failed Stroke Trial in India
10.7.5 Failure of HeartiCellGram-AMI Trial
10.7.6 Failure of Adipose MSCs in ARDS
10.7.7 CD133+ in CLI Not Feasible
10.7.8 Failed MSC Trial for Multiple Sclerosis
10.7.9 Failure of Chinese Diabetes Trial
10.7.10 Failed Efficacy Trial in AMI by Stempeucel
10.7.11 Involvement of Multinational Companies (MNCs in Cell Therapy Sector)

11. The Market For Mesenchymal Stem Cell Therapies
11.1 Market Potential - All Stem Cell Types
11.2. Market Potential - Mesenchymal Stem Cells
11.3 Global Market for Stem Cells by Disease Indication

12. Research And Therapeutic Applications Of MSCs
12.1 Basic Research Applications
12.1.1 MSC Morphology
12.1.2 MSC Detection
12.1.3 Differentiation Capacity
12.1.4 Immuno-modulatory Effects
12.2 Cell Transplantation for Site-Specific Repair
12.2.1 Osteochondral Repair
12.2.2 Myogenic and Myocardial Repair
12.2.3 Neural Repair
12.2.4 Pancreatic Repair
12.3 Directed Differentiation of Mesenchymal Stem Cells
12.3.1 Directed Differentiation of MSCs into Intra-Mesenchymal Lineages
12.3.2 Directed Differentiation of MSCs into Extra-Mesenchymal Lineages
12.4 Drug Delivery Applications: Engineered MSCs as Carriers of Anti-Cancer Drugs
12.5 Drug Screening
12.6 Gene Transfer Studies
12.7 MSC-Mediated Inhibition of Immune Effector Cells
12.8 Supporting Hematopoietic Cell Applications
12.9 Use of 3-D Scaffolds for Tissue Engineering
12.10 Topical Therapy and Use of MSCs in Wound Healing

13. MSC Product Development Variables - Attributes & Acquisition
13.1 Biological Properties of MSCs Contributing to Therapeutic Effects
13.1.1 MSCs’ Capacity to Migrate and Engraft
13.1.2 MSCs’ Differentiation Potential
13.1.3 MSCs’ Potential to Secrete Multiple Bioactive Molecules
13.1.4 MSCs’ Potential for Immunomodulatory Functions
13.1.5 Variable Immunophenotype of MSCs
13.2 Factors Impacting MSCs Acquisition
13.3 Major Clinical Sources of MSCs

14. Clinical Applications Of Mesenchymal Stem Cells
14.1 Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
14.1.1 BMMSCs and Kidney
14.1.2 BMMSCs and Pancreas
14.1.3 BMMSCs and Heart
14.1.4 BMMSCs and Liver
14.1.5 BMMSCs and Brain
14.1.6 BMMSCs and Intestine
14.1.7 BMMSCs and Bone
14.2 Adipose-Derived Mesenchymal Stem Cells (ADSCs)
14.2.1 Clinical Appplicationsof Adipose-Derived Mesenchymal Stem Cells (ADSCs)
14.2.2 Selected ADSC Secretomes and their Functions
14.3 Mesenchymal Stem Cells (MSCs Derived from Wharton’s Jelly
14.3.1 Clinical Application Properties of WJ-MSCs
14.3.2 Immunoprivileged Status of WJ-MSCs
14.3.3 Clinical Applications of WJ-MSCs
14.4 Umbilical Cord Blood-Derived MSCs (UCBMSCs)
14.5 Dominance of MSCs in Cell Therapy Clinical Trials

15. Major Diseases Addressed By MSCs In Current Clinical Trials
15.1 MSCs for Treating Liver Diseases
15.2 MSCs for Neurodegenerative Diseases
15.3 Clinical Trials Using MSCs for Autoimmune Diseases
15.4 Clinical Trials Using MSCs for Diabetes
15.5 MSCs for Cardiovascular Repair
15.6 MSCs for Musculoskeletal Diseases
15.6.1 Studies Using MSCs for Musculoskeletal Indications by Leading Countries
15.6.2 Application of MSCs in Joint Diseases
15.7 MSCs in Neuron/Spinal Cord Diseases
15.8 MSC Infusion for GvHD
15.9 MSCs for Crohn’s Disease
15.10 MSCs in Wound Healing
15.11 Increasing Focus on Immunological Properties of MSCs
15.12 Selected MSCs Late-Stage Pipeline Cell Therapies

16. Market Opportunities For Biobanking Of Mesenchymal Stem Cells
16.1 Types of Mesenchymal Stem Cell Biobanking
16.2 Dental Stem Cell Banking (MSC Biobanking)
16.3 Umbilical Cord Tissue (MSC Biobanking)
16.3.1 Definitions
16.3.2 Cord Tissue Market Overview
16.3.3 Comparison of Cord Blood & Cord Tissue Storage
16.3.4 Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
16.3.5 Market Penetration of Cord Tissue within the U.S.
16.3.6. Pricing of Cord Tissue Storage (Global Analysis)
16.4 Adipose-Derived MSCStorage
16.5 Other Types of MSCBio-Banking: Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More

17. Key Market Metrics Forf MSC
17.1 Global Breakdown of Mesenchymal Stem Cell Clinical Trials
17.1.1 Breakdown of MSC Clinical Trials, By Phase
17.1.2 Additional Resources
17.1.2 Breakdown of MSC Clinical Trials, By Geography
17.1.3 Types of Sponsoring/Collaborating Organizations Supporting MSC Clinical Trials
17.1.4 Specific Industry Participants Supporting MSC Clinical Trial Activity
17.1.5. Summary of Findings for Mesenchymal Stem Cell Clinical Trials
17.2 Patent Analysis
17.2.1 Role of Patent Analysis for Competitive Intelligence
17.2.2 MSC Patent Landscape
17.2.3 Methodology of MSC Patent Analysis
17.2.3 MSC Patents Filed in 2015
17.3 Scientific Publication Analysis
17.4 Grant Rate Analysis
17.4.1 All-Time Analysis of MSC Grants (1997 to Present)
17.4.1.1 Year-over-Year Trends in MSC Grants
17.4.1.2 Geographical Assessment of MSC Grants
17.4.1.3 Assessment of MSC Grants By Subject Matter (1997 to Present)
17.4.1.4 Dominant Principal Investigators
17.4.2 2015 Analysis of MSC Grants
17.4.2.1 List of MSC Grants Funded by NIH-Support in 2015 Fiscal Year
17.4.2.2 Assessment of MSC Grants by Subject Matter (2015)

18. Social Analytics For Mesenchymal Stem Cells
18.1 Marketing Cost Analysis: Search Term “Mesenchymal Stem Cell”
18.1.1 Pay-Per-Click Cost for the Search Term “Mesenchymal Stem Cell”
18.1.2 Analysis of Derivative Search Terms
18.2 MSC Articles Receiving Most Social Media Shares over Past 12 Months
18.2.1 MSC Specific Analysis
18.2.1 Stem Cell Analysis (All Types)
18.3 Google Trend Data for MSCs
18.3.1 Google Trend Data - Mesenchymal Stem Cells Only
18.3.2 Google Trend Data - All Types of Stem Cells
18.4 Twitter Hashtag Data
18.4.1 Twitter Hashtag Data - Mesechymal Specific Data
18.4.2 Twitter Hashtag Data - Stem Cells (All Types)
18.4.3 Top Five MSC Influencers on Twitter
18.4.4 Top Five Stem Cell Influencers on Twitter

19. Selected Company Profiles
19.1 American Type Culture Collection Inc. (ATCC)
19.2 Anterogen Co., Ltd.
19.2.1 Cupistem Injection
19.2.2 Queencell
19.3 Apceth GmbH & Co. KG
19.3.1 Apceth’s Research Areas
19.4 BioCardia Inc.
19.5 BioRestorative Therapies Inc.
19.5.1 brtxDISC
19.5.2 ThermoStem
19.6 Bone Therapeutics SA
19.6.1 PREOB
19.6.2 ALLOB
19.7 BrainStorm Cell Therapeutics Inc.
19.7.1 NurOwn
19.8 CellGenix Technologie Transfer GmbH
19.9 Celprogen Inc.
19.10 CellTherapies P/L
19.10.1 Services
19.10.2 Product
19.11 Cesca Therapeutics Inc.
19.11.1 Surgwerks
19.11.2 Cellwerks
19.11.3 AutoXress (AXP)
19.11.4 MarrowXpress (MXP)
19.11.5 Res-Q BMC
19.12 Cyagen Biosciences Inc.
19.12.1 Mesenchymal Stem Cells from Cyagen
19.12.2 Adipose-Derived Mesenchymal Stem Cells from Cyagen
19.12.3 Mesenchymal Stem Cells with GFP from Cyagen
19.12.4 Adipose-Derived Mesenchymal Cells with GFP from Cyagen
19.12.5 Stem Cell Culture Media from Cyagen
19.12.6 Stem Cell Differentiation Media from Cyagen
19.12.7 Primary Cells from Cyagen
19.12.8 Cyagen’s Cryopreservation Media
19.12.9 Cyagen’s Primary Cell Culture Media
19.12.10 General Cell Culture Supplements and Specialty Reagents from Cyagen
19.13 Cynata Therapeutics Ltd.
19.13.1 Cymerus Platform Technology
19.14 Cytori Therapeutics Inc.
19.14.1 Clinical Trial for Scleroderma
19.14.2 Clinical Trials for Osteoarthritis
19.15 Escape Therapeutics
19.16 Genlantis
19.17 Kite Pharma Inc.
19.17.1 Engineered Autologous Cell Therapy (eACT)
19.17.2 DC-Ad GM-CAIX
19.18 Life Technologies Corporation
19.19 Lonza Group Ltd.
19.19.1 Selected Products
19.20 Medipost Co. Ltd.
19.20.1 Cartistem
19.20.2 Neurostem
19.20.3 Pneumostem
19.21 Mesoblast Ltd.
19.21.1 Mesoblast’s Product Pipeline Overview
19.22 NuVasive Inc.
19.22.1 Osteocel
19.23 Ocata Therapeutics Inc.
19.24 Organogenesis Inc.
19.24.1 Apligraf
19.24.2 Dermagraft
19.25 Orthofix International N.V.
19.25.1 Trinity Elite
19.25.2 Trinity Evolution
19.26 Osiris Therapeutics Inc.
19.26.1 Grafix
19.26.2 OvationOS
19.26.3 Cartiform
19.27 Pluristem Therapeutics Inc.
19.27.1 PLX Cells
19.28 PromoCell
19.29 Regeneus Ltd.
19.29.1 Products
19.30 ScienCell Research Laboratories
19.31 STEMCELL Technologies Inc.
19.32 Stemedica Cell Technologies Inc.
19.32.1 Stemedyne MSC
19.32.2 Stemedyne NSC
19.32.3 Stemedyne RPE
19.33 Stempeutics Research Pvt. Ltd.
19.33.1 Stempeucel
19.33.2 Stempeutron
19.33.3 Stempeucare
19.34 TiGenix N.V.
19.34.1 Cx601
19.34.2 Cx611
19.34.3 Cx621
19.35 Vericel Corporation

List of Tables

Table 1. Adult Sources for Mesenchymal Stem Cell (MSC Isolation)
Table 2. Fetal Sources for Mesenchymal Stem Cell (MSC Isolation)
Table 3. Differentiation Capacity of Mesenchymal Stem Cells
Table 4. Global Breakdown of RM Companies by Region
Table 5. Global Breakdown of RM Companies by Type
Table 6. Number of RM Clinical Trials by Phase
Table 7. Major Financial Events in RM Industry in 2014
Table 8. Major Partnerships and Acquisitions in RM Industry in 2014
Table 9. Major Regulatory Milestones in RM Industry in 2014
Table 10. Major Pharma and Biotech Companies Active in Advanced Therapies
Table 11. Areas of Focus Among Large Pharmaceutical and Biotech Companies Involved with Advanced Therapies
Table 12. Major Corporate Partnerships in RM Industry in 2014
Table 13. Anticipated Major RM Clinical Events in 2015
Table 14. Different Types of Stem Cells Used in Cell Therapy and their Characteristics
Table 15. Mesenchymal Stem Cell Product Candidates in Late-Stage Clinical Development
Table 16. Cell Therapy Products Approved in South Korea
Table 17. Major Companies and Products in Development within Cell Therapy Sector
Table 18. Mesenchymal Stem Cell Research Applications
Table 19. Global Market for Stem Cell Therapies by Disease Indication, Through 2021
Table 20. Origin and Cell Types Derived from MSCs
Table 21. Important Bioactive Molecules Secreted by MSCs and Their Functions
Table 22. Immunomodulatory Effects of MSCs on Immune Cells
Table 23. Cell Surface Antigen Expressions of MSCs Isolated from Different Sources
Table 24. Major Clinical Sources of MSCs
Table 25. A Sample of Clinical Trials using BMMSCs for Kidney Diseases
Table 26. A Sample of Clinical Trials Using BMMSCs for Diabetes
Table 27. A Sample of Clinical Trials Using BMMSCs for Heart Disease
Table 28. A Sample of Clinical Trials Using BMMSCs for Liver Diseases
Table 29. Clinical and Experimental Therapies Using MSCs for Neural Diseases
Table 30. A Sample of Clinical Trials Using BMMSCs for Intestinal Diseases
Table 31. A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases
Table 32. ADSCs Transplantation in Clinical Trials by Region/Country in Phase III
Table 33. Selected ADSC Secretomes and their Functions
Table 34. A Summary of Clinical Trials Using WJ-MSCs
Table 35. Clinical Trials Using UCBMSCs and Targeted Diseases
Table 36. Clinical Trials Using MSCs by Disease Type, 2014
Table 37. A Sample of Clinical Trials Using MSCs for Liver Disorders
Table 38. A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases
Table 39. A Sample of Phase I and II Clinical Trials for Autoimmune Diseases as of 2012
Table 40. A Sample of Clinical Trials Using MSCs for Diabetes
Table 41. A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases
Table 42. Clinical Trials Involving MSCs for Bone and Cartilage Repair
Table 43. Studies Using MSCs for Musculoskeletal Indications by Country
Table 44. A Sample of Current Clinical Trials Using MSCs for Osteoarthritis
Table 45. A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair
Table 46. Sample of Clinical Trials in Different Countries Using MSCs for Neuron and Spinal Cord Diseases
Table 47. Clinical Experience of MSCs in GvHD Treatment
Table 48. A Sample of Clinical Trials Using MSCs for Crohn’s Disease
Table 49. Clinical Studies using MSCs for Wound Healing
Table 50. Number of MSC Scientific Publications about Immune/Inflammation by Year
Table 51. Selected MSCs Late-Stage Pipeline Cell Therapies
Table 52. Types of Mesenchymal Stem Cell Biobanking
Table 53. Companies Offering Dental Stem Cell Storage (Diversified Cord Blood Banks and Specialty Companies
Table 54. Medical Conditions Being Investigated for Potential to be Treated with Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
Table 55. U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013
Table 56. U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015
Table 57. Pricing Structures for Cord Tissue Storage
Table 58. Companies Offering Adipose-Derived MSC Storage (Both Diversified Cord Blood Banks and Specialty Companies)
Table 59. Geographical Breakdown of MSC Clinical Trial Activity
Table 60. Breakdown of MSC Clnical Trial Activity by Sponsoring/Collaborating Organization
Table 61. Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
Table 62. Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
Table 63. Mesenchymal Stem Cell Patents Filed in 2015
Table 64. Analysis of MSC Scientific Publications per Year
Table 65. Number of MSC Grant Rates, by Year (Reporter Analysis)
Table 66. Number of MSC Projects Funded by NIH Support by Year
Table 67. Amount of Funding for MSC Projects Supported by NIH by Year
Table 68. Geographical Assessment of MSC Grants Funded by NIH Support
Table 69. Leading Principal Investigators for MSC Research
Table 70. MSC Grants Funded by NIH-Support in 2015 Fiscal Year
Table 71. Breakdown of MSC Grants Funded by NIH-Support by Subject
Table 72. Google Adwords Pay-Per-Click (PPC Costs for MSCs
Table 73. Most Shared MSC Articles of the Past 12 Months
Table 74. Most Shared Stem Cell Articles of the Past 12 Months (All Stem Cell Types)
Table 75. Google Trend Data Showing Related Searches for “Mesenchymal Stem Cells” over a 5-Year History
Table 76. Google Trend Data Showing Related Searches for “Stem Cells” over a 5-Year History
Table 77. Rates of Twitter Usage by Country
Table 78. Top 10 Hashtags Related to “#Mesenchymal” on Twitter
Table 79.Top 10 Hashtags Related to “#StemCells” on Twitter
Table 80. Top 5 MSC Influencers on Twitter
Table 81. Top Five Stem Cell Influencers on Twitter
Table 82. BioCardia’s Product Pipeline Overview
Table 83. Bone Therapeutics’ Product Pipeline
Table 84. Cyagen’s Mesenchymal Cells
Table 85. Cyagen’s Adipose-Derived MSCs
Table 86. Gyagen’s MSCs with GFP
Table 87. Adipose-Derived Mesenchymal Cells with GFP
Table 88. Cyagen’s Stem Cell Culture Media
Table 89. Cyagen’s Stem Cell Differentiation Media
Table 90. Primary Cells from Cyagen
Table 91. Cyagen’s Cryopreservation Media
Table 92. Cyagen’s Primary Cell Culture Media
Table 93. General Cell Culture Supplements and Specialty Reagents from Cyagen
Table 94. Escape Therapeutics’ Pipeline Products
Table 95. Kite Pharma’s Pipeline and Clinical Trials
Table 96. Mesoblast’s Product Pipeline Overview
Table 97. Ocata’s Pipeline of Therapeutic Programs
Table 98. Regeneus’ Product Pipeline
Table 99. Stempeucel in Clinical Trials by Indication
Table 100. Vericel Corporation’s Product Portfolio
Table 101. Summary Table for the Companies and Their Product Types

List of Figures

Figure 1. Benefits of MSCs Relative to Other Stem Cells
Figure 2. Global Breakdown of RM Companies by Region
Figure 3. Major Financial Events in RM Industry in 2014
Figure 4. Major Partnerships and Acquisitions in RM Industry in 2014
Figure 5. Major Regulatory Milestones in RM Industry in 2014
Figure 6. Five Types of Stem Cells, by Differentiation Potential
Figure 7. Global Market for Stem Cell Therapies by Disease Indication, Through 2021
Figure 8. Clinical Trials Using MSCs by Disease Type, 2014
Figure 9. Number of MSC Scientific Publications about Immune/Inflammation by Year
Figure 10. Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
Figure 11. Percentage of Mesenchymal Stem Cell (MSC Clinical Trials by Phase
Figure 12. Geographical Assessment of MSC Clinical Trial Activity
Figure 13. Breakdown of MSC Clinical Trial Activity by Sponsor/Collaborating Organization
Figure 14. Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
Figure 15. Analysis of MSC Scientific Publications per Year
Figure 16. 5-Year Projections for MSC Scientific Publication Rates (2016-2020)
Figure 17. Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; U.S. Only)
Figure 18. Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; U.S. Only)
Figure 19. Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; Geography: Worldwide)
Figure 20. Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; Geography: Worldwide)
Figure 21. Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: USA Only)
Figure 22. Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: Worldwide)
Figure 23. Comparison of Google Trend Data for “Mesenchymal Stem Cells” (Plural vs. “Mesenchymal Stem Cell” (Singular over a 10-Year History)
Figure 24. Google Trend Data for “Mesenchymal Stem Cells” over a 5-Year History
Figure 25. Google Trend Data Showing Regional Interest in “Mesenchymal Stem Cells” over a 5-Year History
Figure 26. Google Trend Data Showing City-by-City Interest in “Mesenchymal Stem Cells” over a 5-Year History
Figure 27. Groundbreaking Years in Hematopoietic Stem Cell Transplant History
Figure 28. Google Trend Data for “Stem Cells” over a 10-Year History
Figure 29. Google Trend Data - Comparison of All Types of Stem Cells over a 5-Year History
Figure 30. Google Trend Data Showing Regional Interest in “Stem Cells” over a 5-Year History
Figure 31. Google Trend Data Showing City-by-City Interest in “Stem Cells” over a 5-Year History
Figure 32. Top 10 Hashtags Related to “#Mesenchymal” on Twitter
Figure 33. Top 10 Hashtags Related to “#StemCells” on Twitter

Note: Product cover images may vary from those shown
3 of 4

- American Type Culture Collection Inc. (ATCC)
- Anterogen Co., Ltd.
- Apceth GmbH & Co. KG
- BioCardia Inc.
- BioRestorative Therapies Inc.
- Bone Therapeutics SA
- BrainStorm Cell Therapeutics Inc.
- CellGenix Technologie Transfer GmbH
- Celprogen Inc.
- CellTherapies P/L
- Cesca Therapeutics Inc.
- Cyagen Biosciences Inc.
- Cynata Therapeutics Ltd.
- Cytori Therapeutics Inc.
- Escape Therapeutics
- Genlantis
- Kite Pharma Inc.
- Life Technologies Corporation
- Lonza Group Ltd.
- Medipost Co. Ltd.
- Mesoblast Ltd.
- NuVasive Inc.
- Ocata Therapeutics Inc.
- Organogenesis Inc.
- Orthofix International N.V.
- Osiris Therapeutics Inc.
- Pluristem Therapeutics Inc.
- PromoCell
- Regeneus Ltd.
- ScienCell Research Laboratories
- STEMCELL Technologies Inc.
- Stemedica Cell Technologies Inc.
- Stempeutics Research Pvt. Ltd.
- TiGenix N.V.
- Vericel Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

ALSO AVAILABLE

RELATED PRODUCTS from Cache

Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.